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Abstract
Background: A Java™ application is presented, which compares large numbers (n > 100) of raw FTICR mass spectra from
patients and controls. Two peptide profile matrices can be produced simultaneously, one with occurrences of peptide masses
in samples and another with the intensity of common peak masses in all the measured samples, using the peak- and background
intensities of the raw data. In latter way, more significantly differentially expressed peptides are found between groups than just
using the presence or absence in samples of common peak masses. The software application is tested by searching angiogenesis
related proteins in glioma by comparing laser capture micro dissected- and enzymatic by trypsin digested tissue sections.
Results: By hierarchical clustering of the presence-absence matrix, it appears that proteins, such as hemoglobin alpha and delta
subunit, fibrinogen beta and gamma chain precursor, tubulin specific chaperone A, epidermal fatty acid binding protein,
neutrophil gelatinase-associated lipocalin precursor, peptidyl tRNA hydrolase 2 mitochondrial precursor, placenta specific
growth hormone, and zinc finger CCHC domain containing protein 13 are significantly different expressed in glioma vessels. The
up-regulated proteins in the glioma vessels with respect to the normal vessels determined by the Wilcoxon-Mann-Whitney test
on the intensity matrix are vimentin, glial fibrillary acidic protein, serum albumin precursor, annexin A5, alpha cardiac and beta
actin, type I cytoskeletal 10 keratin, calcium binding protein p22, and desmin. Peptide masses of calcium binding protein p22,
Cdc42 effector protein 3, fibronectin precursor, and myosin-9 are exclusively present in glioma vessels. Some peptide fragments
of non-muscular myosin-9 at the C-terminus are strongly up-regulated in the glioma vessels with respect to the normal vessels.
Conclusion: The less rigorous than in general used commercial propriety software de-isotope algorithm results in more mono-
isotopic peptide masses and consequently more proteins. Centroiding of peptide masses takes place by taking the average over
more spectra in the profile matrix. Cytoskeleton proteins and proteins involved in the calcium signaling pathway seem to be
most up-regulated in glioma vessels. The finding that peptides at the C-terminus of myosin-9 are up-regulated could be ascribed
to splicing or fragmentation by proteases.
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Background
Gliomas are the most common primary brain tumors,
which resort among the neoplasms with the highest
degree of blood vessel formation. The identification of
new angiogenesis-related proteins is important for the
development of anti-angiogenesis therapy. In a previous
study [1], angiogenesis related proteins were identified in
micro-dissected glioma vessels using Matrix Assisted Laser
Desorption Ionization Fourier Transform Ion Cyclotron
Resonance (MALDI-FTICR) Mass Spectrometry (MS). In
brief, four different micro-dissected tissue groups were
compared, namely, 1) samples from glioma blood vessels,
2) samples from glioma tissue surrounding these glioma
vessels, 3) samples blood vessels in normal brain, and 4)
samples from tissue that surrounded the normal vessels.
The study resulted in the discovery of enzymatic by trypsin
digested peptide fragments of proteins, which are exclu-
sively present in samples of the glioma blood vessels using
MS. The presence of two of these proteins was confirmed
with specific antibodies on various tissue sections includ-
ing glioma. The combination of techniques led to the dis-
covery of validated biomarkers for glioma vessels,
respectively, fibronectin precursor with SwissProt™ acces-
sion code P02751, collagen-binding protein 2, also
named colligin-2 with SwissProt™ accession code P50454,
and one candidate marker acidic calponin-3 with Swiss-
Prot™ accession code Q15417. The presence of fibronectin
precursor and colligin-2 was confirmed by staining of tis-
sue sections with specific commercial antibodies. Staining
of fibronectin and colligin-2 by immunohistochemistry
in glioma vessels is shown in Figure 3 and Figure 4 of ref.
[1]. However, it is desirable to find more than these 3 pro-
teins as candidate biomarkers. Ideally, the finding of more
specific proteins will help to elucidate protein pathways
that function in angiogenesis. Sophisticated bioinformat-
ics may retrieve more information from present MS data.
In a previous manuscript, a database application is pre-
sented, which enables to compare hundreds of MALDI-
TOF MS spectra from patient and control groups [2]. In
this study, the application, written in Java™ [3], is adapted
to handle hundreds of mass spectra, which are measured
on a FTICR MS instrument. This required complete rewrit-
ing of some parts of the source code, avoiding computer
memory and performance issues dealing with high resolu-
tion FTICR MS spectra. The new architecture can also com-
pare intensities of spectra as we address later. This was not
possible in the previous version. The high resolution of
MALDI FTICR spectra with respect to MALDI-TOF spectra
enables de-isotoping, which we implemented in current
version. In addition, the application can handle LC
MALDI MS peak lists, which de-convolutes peptide
masses with extra dimension elution time. Table 1 gives
an overview of all the instruments and file types of
exported mass spectra that are accessible for the applica-
tion. The files types may consist of raw binary MS spectra
or exported peak lists containing masses and correspond-
ing intensities or XML files. The use of peak lists or XML
files with respect to the use of raw binary data (the fid
files) has the disadvantage of the so called "missing data"
problem, which is demonstrated in Table 2a. When com-
paring peak lists, it appears that the signal intensity from
a specific peak in a sample is not matched with intensities
of peptide masses from other samples. This problem is
tackled by using the raw binary data generated from the
mass spectrometer instead of peak lists. The database
application is adapted to handle raw binary fid (free
induction decay) files. The data in these files is processed
by Fast Fourier Transformation (FFT) into a frequency sig-
nal. By this conversion the mass can be calculated from
the frequency, using the calibration constants in the acqus
(acquisition status) files. The average signal intensity of
noise, the baseline, is calculated according to a method
developed by Horn et al. [4]. Figure 1 shows a fragment of
an MALDI-FTICR MS spectrum as generated from the raw
binary fid file. The baseline is the bottom horizontal line
in Figure 1. The scatter of noise intensities around the
baseline as seen in Figure 1 is expressed in a variable noise
N. Real peaks are expected to display a signal, S, with an
intensity above the sum of 2 intensities, namely 1) the
baseline intensity, and 2) the factor*N. The combined
intensity is denoted as signal to noise, S/N, threshold. The
signal to noise threshold is the upper horizontal line in
Figure 1. The peaks at masses 1808.9034 and 1809.9062
Da have intensities above the S/N threshold. The masses
1808.9034 and 1809.9062 Da are added in the peptide
profile matrix with number of occurrences of a peptide
mass for different samples [2]. Average masses over all
spectra are calculated from these masses in the different
samples with intensities above the S/N threshold. When
working with raw data creating the intensity matrix, it is
possible to register the background noise signals by
recording all the peaks, such as approximately at 1810.9
and 1811.9 Da in Figure 1 with intensities between the
baseline and the S/N threshold in a separate "noise peaks"
file. These masses are not added to common peak list of
the peptide profile matrix. Solely the background intensi-
ties > 0 but smaller than the S/N threshold of these "noise
peaks" file are used for calculations. All signals below the
baseline are neglected. This approach results in a more
reliable and complete comparison of the intensities of
peak masses in different groups (Table 2b). For each mass
of the common peak list a Wilcoxon-Mann-Whitney rank
sum test can be performed comparing the intensities of
this mass in the samples of two groups. The p-value of the
Wilcoxon-Mann-Whitney test ranks peak masses, that
have for instance intensities that are strong up-regulated
in the glioma vessel group compared to the normal con-
trol vessel group, and vice versa. In this way, we can find
more significantly differentially expressed peptides, than
just using the presence-absence matrix of peak masses. InBMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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a presence-absence matrix the presence of a specific mass
in a sample, part of a common peak list of the masses in
all samples, is represented by 1, and the absence is repre-
sented by 0. The process of generating the binary matrix is
explained in [2] with that difference that in this FTMS
study no replicate spectra of samples are measured, result-
ing in counted values of just 1 and 0. The peak lists of the
samples are processed from raw data with high sensitivity
at a relative low S/N threshold of 4. It is well known that
MALDI TOF MS analysis suffers from limited reproduci-
bility in term of peak intensities. The peak intensities
measured with the FTICR MS, however, vary about 10% in
replicate spectra of a single sample. The peak intensities
are not normalized, because experimental conditions are
kept constant, e.g. number of laser shots. A simple, but
effective de-isotope algorithm is introduced, which is able
to remove most of the isotopic masses from the raw data.
The resulting peak list of one sample is compared with
that obtained with commercially DataAnalysis™ software
(Bruker Daltonics, Germany), which uses the SNAP™ de-
isotope algorithm. The tryptic protonated peptide frag-
ments of proteins are compared with those theoretically
calculated from the proteins in the SwissProt™ database,
using the MASCOT™ search engine [5] and MS-MS
sequencing of MALDI-TOF MS data of Liquid Chromatog-
raphy (LC) fractionated samples using the WARP-LC™
software (Bruker Daltonics, Germany) as described in [1].
Mass accuracy
In the peak picking algorithm the data point are used with
the local highest intensity without an m/z centroiding. In
Equation (2) to (5) the frequency and the mass difference
between the data points is given to describe the inaccuracy
due to this simple peak detection. We do not consider
mass accuracy due to peak broadening by space charging.
In our experiments, we accumulate the ions of 10 laser
shots in the storage hexapole for each scan, and a total of
100 scans is used for each mass spectrum. Storing the ions
in the hexapole prior to ICR analysis prevents overloading
of the ICR cell. The mass accuracy in ppm of peak maxima
in FTICR spectra can theoretically be calculated for the
A fragment of a MALDI-FTICR MS spectrum as generated from the raw binary fid file Figure 1
A fragment of a MALDI-FTICR MS spectrum as generated from the raw binary fid file. The baseline is the bottom 
horizontal line. The signal to noise threshold is the upper horizontal line. The peaks at masses 1808.9034 Da and 1809.9062 Da 
have intensities above the S/N threshold. The masses at 1808.9034 and 1809.9062 Da are used to create the peptide profile 
matrix. The intensities of all four peaks, including the background signal at approximately masses at 1810.9 and 1811.9 Da are 
used in the intensity peptide profile matrix.BMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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FTICR MS device used as described in any advanced MS
textbook [6]. Recapitulated, the dimensionless value of
 is inversely proportional to the frequency f in Hz of
the FTICR signal for a particle with charge z*e (C) and
mass m*u (kg).
where the device specific calibration constant in the acqus
file ML1 ≈ 1.443*108 Hz is used for calculating peak
masses from frequencies. A derivative of above equation
originates in the following equation [6]:
The frequency resolution Δf is:
where the frequency sweep SW_h is 1.818*105 Hz; the
number of data points TD = 524288 and a chosen factor
zerofilling is 4. Equation (3) shows that zero filling
increases the mass accuracy [7]. Applying these values
results in:
The average distance between the real maximum and the
raw spectrum data point is   the distance between the
data points. Therefore the absolute value of mass accuracy
for a 9.4 T ICR magnet is:
For a dimensionless   value of for instance 1000 equal
to Daltons for single charged MALDI masses, a mass accu-
racy of 0.6 ppm can be calculated and for a dimensionless
 value of 2500, a mass accuracy of 1.5 ppm can be the-
oretically be expected. The average value of mass accuracy
for a   between a 1000 and 2500 is 1.05 ± 0.27 ppm.
Given these values, corresponding peptide masses of pro-
teins where searched in the SwissProt™ database with
MASCOT™ using a mass tolerance of peptides of no more
than 2 ppm.
De-isotope algorithm
A simple, but effective, de-isotope algorithm is imple-
mented in the database application based on the method-
ology described earlier [8]. The de-isotope algorithm starts
with the determination of a number of isotopic clusters of
peaks above the signal to noise threshold (Figure 1),
denoted as C, in the mass spectrum, where the difference
in peptide mass between the mono-isotope   and first
isotope   in each cluster, j, is  ,
and the difference in mass of the first and second isotope,
, and so on. The theoretical iso-
topic difference   reported for the
first isotope in Figure 1a of ref. [4] is about 1.00289 Da.
The relative atomic abundance in the theoretical amino
acid "averagine" is 31.71% C, 49.82% H, 8.72% N, 9.49%
O, and 0.27% S [9], while the abundance of the first iso-
tope C13 is 1.11% with an isotopic difference mass C13 –
C12 = 1.00335 Da, 0.015% H2 with 1.00628 Da, 0.370%
N15  with 0.99704 Da, 0.037% O17  with 1.00423 Da,
0.700% S33 with 0.99939 Da [10]. Based on a weighted
mean, a value of 1.00289 Da can be calculated for the first
isotope. Horn et al. [4] calculate the isotopic distances
also for higher isotopes with an average value of 1.00235
Da. When applying an input isotopic distance of 1.00235
Da [4] in the application, the average isotopic distance in
the best clusters as will be described shortly in 38 samples
is 1.00327 Da. Clearly the isotopic distance in the best
clusters is predominantly influenced by the C13 isotopic
difference of 1.0034 Da, an experimental value which we
most frequently observe in our spectra. This might be due
to ion statistics, because with low concentrations of sam-
ple, average values are not measured. The value 1.0034 Da
is used as a default setting in the application. The intensity
of the mono-isotope peak in the mass spectrum may be
larger than the intensity of the first isotope in the low
mass area m/z < 1800, or the intensity of the mono-iso-
tope peak may be smaller than the first, second, or higher
isotope peak when m/z > 1800 [11,12]. However, in both
cases the intensity of subsequent isotopes in a cluster
never increases, once it has decreased (at least not with
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non-overlapping isotopic clusters). Furthermore, a mono-
isotope peak in this algorithm does not have an accompa-
nying isotopic peak with an approximately 1.0034 Da
smaller mass. These considerations are taken into account
when determining the peptide masses that belong to true
isotopic clusters. Within each isotopic cluster all peptide
masses are gathered which have an m/z distance with the
previous isotope of 1.0034 ± 0.0100, thus with an initial
relative high mass tolerance of 1%. The average isotopic
distance of each cluster j is calculated according to:
Where Nj is the number of peptide masses in an isotopic
cluster, j, including the mono-isotope,  . From the total
amount of clusters C, a number of clusters are selected; Cs
(≤ C) that shows the smallest intra isotopic distance vari-
ance, for example less than 0.1%. For each selected cluster
j:
In this case the variable variance_isotopic_distance = 0.1.
If at least 10 good clusters are found, Cs ≥ 10, a new aver-
age isotopic distance, μs, is calculated from the mean iso-
topic distance, μj, of the selected clusters, j.
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Table 1: Overview of all the instruments and MS file types that can be handled by the database application.
Equipment Type File names File content
Ultraflex ™ MALDI-TOF (Bruker Daltonics) fid fid, acqus, acqu raw binary data, calibration constants
text *.txt mass and intensity peak list, space or tab separated
APEX-Q 9.4T MALDI-FTICR (Bruker Daltonics) fid fid, acqus, acqu raw binary data, calibration constants
text *.txt mass and intensity peak list, space or tab separated
xml exportedSpectrum.xm
l
<pk mz="mass1" i="intensity1"/>
Off-line LC-MALDI (TOF/TOF) (file-export WARP-LC™ 
software, Bruker Daltonics)
text *.txt mass, intensity and Retention time peak list, space or 
tab separated data
xml *.xml <Compound mass="mass1"
RetentionTime="retentiontime1"
AbsoluteIntensity="intensity1"> </Compound>
The database application is written in Java and R and uses a MySQL™ database. The files types may consist of 1) raw binary MS spectra (the fid 
files), 2) exported peak lists containing tab or space separated masses and corresponding intensities, and 3) XML files.
Table 2: A fragment of mass and intensity peaks lists of 2 
samples, illustrating the "missing data" problem.
A)
Sample 1 Sample 2
Mass (Da) Intensity (A.U.) Mass (Da) Intensity (A.U.)
? ← 1193.6166 756021
? ← 1194.5728 191048
1194.6477 175777 1194.6477 271465
1197.1376 126487 → ?
? ← 1197.6611 124472
? ← 1198.5193 162275
1198.7047 3154774 1198.7047 2435350
B)
Sample 1 Sample 2
Mass (Da) Intensity (A.U.) Mass (Da) Intensity (A.U.)
0 ← 1193.6166 756021
114322 ← 1194.5728 191048
1194.6477 175777 1194.6477 271465
1197.1376 126487 → 80604
0 ← 1197.6611 124472
0 ← 1198.5193 162275
1198.7047 3154774 1198.7047 2435350
A) Missing data problem. It appears that the signal intensity from of a 
peptide mass of 1193.6166 Da in sample 2 is not matched with an 
intensity of the peptide mass from another sample 1 and vice versa 
the intensity of peptide mass of 1197.1376 Da of sample 2 is not 
observed in sample 1.
B) More reliable comparison including background noise signal by 
recording all the peaks with intensities between the baseline and the 
S/N threshold in a "noise peaks" file.
A.U. = arbitrary unitsBMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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The mean isotopic distance μs of the selected clusters has
a deviation of:
True isotopic clusters must have a mean isotopic distance,
μj, between μs – σs and μs + σs. Figure 2 shows the distribu-
tion of the mean isotopic distance, μj of potential isotopic
clusters of sample H2 as a function of the mono-isotopic
masses. The dashed line in Figure 2 represents the accept-
ance window of mean isotopic distances real clusters, μs –
σs and μs + σs. As shown in Figure 2, the larger mass accu-
racy at larger peptide masses is reflected by the larger scat-
ter of isotopic distances μj. All isotopic masses of the
clusters, that have a mean isotopic distance within the
acceptance window, μs – σs and μs + σs, are removed from
the peak lists. If the mean isotopic distance value of a
potential isotopic cluster in not in the acceptance win-
dow, isotopic masses are peeled from this cluster from
high to low mass until the mean isotopic mass is within
the acceptance window, the remaining isotopes are
removed from the peak list. As an example, the masses
1300.529351, 1301.531681, and 1302.525368 Da are
detected as a potential isotopic cluster. However, the
mean isotopic distance is too low with 0.9980 Da, due to
the low distance between the first and second isotope of
0.9937 Da. The peak at mass 1302.525368 Da appears
not an isotopic signal after visual inspection of the mass
spectrum. Consequently, only the isotopic mass
1301.531681 Da with distance 1.0023 Da from the
mono-isotope is removed from the peak list.
Methods
Tissue Sections
Identical raw MS fid files of 40 micro-dissected tissue sec-
tions were used as described in [1]. The 10 spectra of gli-
oma blood vessels were coded H1 to H10, 10 spectra of
tissue surrounding the glioma vessels were coded TH1 to
TH10, 10 spectra of normal vessels were coded S1 to S10,
and 10 spectra of tissue surrounding the normal vessels
were coded TS1 to TS10.
MS-MS sequencing of peptides in tissue sections
Proteins were identified by the MS-MS sequencing as
described in [1]. In brief, a number of 4 pooled samples
were subjected to nano-LC fractionation. First, 8 sections
comprising tissue and vessels of sample TH8 were com-
bined (of which 10% was estimated to be vessels). Sec-
ondly, for comparison 8 sections of the normal brain
sample TS5 were combined in exactly the same way. In
addition, micro-dissected glioma samples of series H1 to
H10 were combined, resulting in one pooled glioma
blood vessel sample. Finally, the 10 samples of normal
vessels in series S1 to S10 were pooled according to the
same procedure. With time intervals of 15 s, fractions of
the samples were spotted automatically upon a 384 pre-
spotted anchor-chip plate. The plates were measured by
an automated Ultraflex™ MALDI TOF-TOF instrument
(Bruker Daltonics, Germany), using WARLP-LC™ soft-
ware. The WARLP-LC™ software interprets MS spectra of
each individual spot and subsequently performs MS-MS
on each peptide peak mass. The best peak masses for per-
forming the MS-MS sequencing were determined auto-
matically by the WARLP-LC™ software. The BTDX.xml
export files, containing the MS and the MS-MS peak
masses, were imported in Biotools™ software version 3.0
(build 1.68) (Bruker Daltonics, Germany) and submitted
by this software application to the SwissProt™ version
40.21 database, using the MASCOT™ search engine. A 150
ppm parent mass tolerance, 0.5 Da fragments tolerance,
and one possible missed trypsin cleavage site was allowed.
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Distribution of the mean isotopic distances μj of real isotopic  clusters as a function of the mono-isotopic peptide mass in  the glioma vessels sample H2 Figure 2
Distribution of the mean isotopic distances μj of real 
isotopic clusters as a function of the mono-isotopic 
peptide mass in the glioma vessels sample H2. The 
dashed lines represent the acceptance window, between μs – 
σs and μs + σs of mean isotopic distances of real isotopic clus-
ters. The larger mass accuracy with larger peptide masses is 
reflected by the larger scatter of isotopic distances μjBMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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MALDI-FTICR MS measurements
The samples of H1 toH10, S1 to S10, TH1 to TH10, and
TS1 to TS10 were enzymatic digested by trypsin, mixed
with 2,5-dihydroxybenzoic acid (DHB) solution (1 mg/
ml H2O), spotted upon a 600/384 anchor-chip plate
(Bruker Daltonics, Germany), and measured by an type
APEX-Q™ FTICR MS instrument with a 9.4 T magnet
(Bruker Daltonics, Germany). The details of this proce-
dure is described in [1]. The mono-isotopic peak list of gli-
oma sample H7 obtained with the new de-isotope
algorithm of the database application was compared with
that obtained by the SNAP™ algorithm using DataAnaly-
sis™ version 3.4 (Build 169) software using an S/N > 1.7.
The SNAP™ de-isotope algorithm is performed with the
following parameters; the instrument type is set default
(Fourier transform), the quality factor threshold 0, the S/
N threshold 1.7, the relative intensity threshold (base
peak) 0.01%, the absolute intensity threshold 0, the max-
imum charge state 4, the repetitive building block of C
4.9384 N 1.3577 O 1.4773 S 0.0417 H 7.7583 (the theo-
retical "averagine" amino acid composition [13]), the
additional constant unit "empty", the algorithm version
2.0, an include component isotope pattern checkbox "not
checked", the filter exclusion masses checkbox "not
checked", the use peak finder to calculate peak position
checkbox "checked".
Data analysis
The Java™ software package described in [2] was adapted
to handle raw FTICR MS data and was used to create a pro-
file matrix of all peptide masses present in the 40 samples
from the MALDI-FTICR mass spectra. The application was
adapted to annotate peptide peak masses from raw FTICR
MS fid files (Bruker Daltonics, Germany), which had
intensities above an S/N threshold of 4. The search win-
dow for peaks was 20 ppm in both directions, which
could be varied in the Graphical User Interface (GUI) of
the application [2]. A window of 20 ppm was chosen,
because of the experimental constraints of the simple
peak picking (no interpolation between data points or
curve fittings). The peak picking algorithm searches for a
local maximum in this window in the MALDI-FTICR MS
spectrum. A too small window of 3 ppm generates too
large peak lists and causes performance problems. The
software package was written in Java™ and R [14] and used
a MySQL™ database [15]. It required special libraries to be
installed, namely edtftpj-1.4.8.jar, mysql-connector-java-
3.1.6-bin.jar and serializer.jar [15-17].
Apodization Function
The following apodization function Fk was multiplied
with the raw FTICR time signal of each data point, k,
before applying the FFT:
Where the number of data points TD = 524288 (with no
factor for zero filling) and 1 ≤ k ≤ TD. LB and GB represent
the Lorentzian and Gaussian broadening factors. The
spectra were processed with a LB of 0 and a GB of
0.3276932. The values of these factors are default settings
of the application GUI.
Internal calibration
All mass spectra of the samples were internally calibrated
on ubiquitous cytoplasmic 1 beta actin single charged
peptide masses of 1198.70545, 1515.74913, 1790.89186,
2215.06990 and 3183.61423 Da (see additional file 1).
The protein cytoplasmic 1 beta actin has the SwissProt™
accession code P60709. The internal calibration required
that measured actin masses had to be within 30 ppm dis-
tance of the calibration masses with allowance of one
missing actin mass, resulting in at least 4 calibration
points for each calibrated spectrum. A shift of 30 ppm was
chosen since this value is somewhat smaller than the
broadness of peaks at the baseline in the FTICR MS spectra
with our settings and larger than the expected shift of mass
values. A too small value < 5 ppm would result in a to
small amount calibration masses and result in excluding
the spectrum. A too large value > 30 ppm would result in
the usage of peptide masses from wrong proteins other
than actin. The shift by internal calibration is smaller than
5 ppm. The value of 30 ppm can be changed in the GUI of
the application. An insufficient number of calibrate
masses were found with the "normal vessel" sample S5
and "tissue surrounding the normal vessels" sample TS5
and they were not used for further analysis. If more than
three calibration masses are found within 30 ppm of the
measured peak masses, the following quadratic equation
is applied to calculate the constants a [0], a[1], and a[2]
from the observed frequencies of the peak masses, using
R's linear model lm [14].
All peak masses were subsequently recalculated from the
observed frequencies using this formula.
Peptide profiles
Two different peptide profile matrices were produced
simultaneously, one with the presence or absence of com-
mon peptide masses in spectra of different samples, and a
matrix with the intensity of the peak mass if present in the
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sample or the intensity of the background signal if absent
[2]. To avoid including too many noise peaks in the
matrix, each peptide mass had to be present 10% of the
spectra (= 4). The binary presence-absence matrix was
transposed in Spotfire™ Decision Site 9 (SP1) version
17.2.783 [18] and an unsupervised hierarchical clustering
in two dimensions was performed. The clustering was
done in a number of steps, first transposing the peptide
profile matrix, clustering the samples and sorting on hier-
archical clustering id, than transposing the table again,
and clustering the masses the second time. The clustering
method used in Spotfire™ was the Un-weighted Pair
Group Method with Arithmetic Mean (UPGMA) using the
Euclidean distance and ordering function average value.
The added column name was Hierarchical clustering and
the checkbox calculate dendrogram checked. On the
intensity matrix [2], a Wilcoxon-Mann-Whitney rank sum
test was performed. The Wilcoxon-Mann-Whitney p-val-
ues for peptide masses were calculated for their difference
in peak intensities in the normal and glioma blood vessels
group. The p-values of the Wilcoxon-Mann-Whitney test
on the glioma and normal vessel group are given in Addi-
tional file 2. The most up-regulated peptide masses in the
glioma vessels with the lowest p-values were 1) compared
with masses of the MS-MS sequencing table in the addi-
tional material (Additional file 1), and 2) used in MAS-
COT™ to search calculated peptides of proteins with a
mass tolerance of 2 ppm difference with the experimental
values. Two analysis rounds were performed, respectively
with peptides masses that had p-values < 0.01 and p-val-
ues < 0.1.
Mass accuracy
The experimental mass accuracy was determined from the
mean value of the absolute differences between the meas-
ured and theoretical masses of tryptic peptide fragments
of 2 proteins; 1) GFAP with entry name GFAP_HUMAN
and SwissProt™ accession number P14136, and 2) type I
cytoskeletal 10 keratin, with entry name K1C10_HUMAN
and SwissProt™ accession number P13645. The protein
K1C10_HUMAN was determined by the WARP-LC™ soft-
ware to be present in 2 pooled samples; 1) glioma vessels,
and 2) normal vessels (see Additional file 1). The protein
GFAP_HUMAN was determined by the WARP-LC™ soft-
ware to be present in all the 4 pooled samples; 1) glioma
vessels 2) glioma tissue and vessels, 3) normal vessels, and
4) normal tissue and vessels (see Additional file 1). Kera-
tin and Glial Fibrillary Acidic Protein were selected, since
the tryptic peptide masses from these proteins appeared to
be present in all the MALDI-FTICR MS spectra. From in
total about 60 peak masses, the mass accuracy was deter-
mined from 20 peak masses that had the highest mean
peak intensities, 20 peak masses with middle mean peak
intensities, and 20 peak masses with the lowest mean
peak intensities. The mean peak intensity of each mass
was calculated from peak and background intensities
from the present signals in the intensity matrix.
Results
MS-MS peptide sequencing of tissue sections
All MS-MS sequencing analysis results of 1) the glioma
vessels samples, 2) glioma tissue and vessels samples, 3)
normal vessels samples, and 4) normal tissue and vessels
samples generated by the WARP-LC™ software are pre-
sented in the additional material (Additional file 1).
Peak finding and de-isotope algorithm
The peak finding algorithm in our database application
results in a peak list of 2026 peptide peak masses with a S/
N threshold of 4 for sample H7 (Additional file 3). The
DataAnalysis™ 3.4 (Build 169) software gives approxi-
mately the same number of 2064 peak masses (≈ 2026) at
a S/N threshold of 1.7 (Additional file 4). The definition
of S/N threshold for peak finding is different in both soft-
ware applications. The overlap of both peak lists is about
90% with 1834 peptide masses. A large decrease with 82%
to 379 peak masses is assigned when the SNAP™ de-iso-
tope algorithm is applied on the peak list exported from
the DataAnalysis™ software (Additional file 5). A more
modest decrease with 28% to 1451 peak masses is seen
with the de-isotope algorithm described in this publica-
tion (Additional file 6). A number of about 250 isotopic
clusters fall within the acceptance window (Figure 2),
with an average of 3 isotopes (including the mono-iso-
tope). When about 500 isotopes are remove from the peak
list (≈ 2026 – 1451), it appear that the main amount of
the 1451 peaks, namely ± 1200 (≈ 1451 – 250) are single
peaks with intensities just above the signal to noise
threshold. A percentage of 83% (314 peak masses) of the
DataAnalysis™ mono-isotopic peak masses appears to be
present in the mono-isotopic list of the database applica-
tion. At a higher S/N ratio of 4 instead of 1.7, using the
DataAnalysis™ software, the number of total annotated
peak masses gradually drops to 654, while the number of
mono-isotopic peaks established with the SNAP™ algo-
rithm yields 283 peak masses. This is a smaller decrease of
57% than the 82% measured at a low signal to noise
threshold of 1.7. It indicates that the mono-isotopic peaks
that are detected with the SNAP™ algorithm are in the high
intensity peptide clusters.
Mass accuracy
In Table 3, the measured mass accuracy of an exported
peak list of a single sample H7 from the database applica-
tion is about 1.10 ± 0.91 ppm. This mass accuracy is about
equal to the theoretical value of 1.05 ± 0.27 ppm. The
masses in the peak list of the same sample exported with
the DataAnalysis™ (Bruker Daltonics, Germany) software
are more accurate with a low value of 0.81 ± 0.59 ppm.
The higher accuracy is probably due to another internalBMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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calibration formula and a sophisticated propriety centro-
iding algorithm. When taking into account the average of
the peptide masses in all the samples, the measured mass
accuracy in the database application from raw data
decreases from 1.10 ± 0.91 to 1.03 ± 0.72 and further to
0.67 ± 0.48 ppm when determined on peptide masses,
which appear to be presents in at least 5 or more and 18
or more samples in the peptide matrix of in total 38 sam-
ples, respectively. The peak masses with the highest inten-
sities do not necessary have a higher mass accuracy,
namely 0.91 ± 0.58 ppm, than peak masses with middle
mean peak intensities, 0.66 ± 0.39 ppm. Peak masses with
the lowest mean peak intensities have the worst mass
accuracy, 1.54 ± 0.82 ppm, but are also calculated with the
smallest number of 254 peak and background signals.
Hierarchical clustering
Figure 3 shows the hierarchical clustering on the presence-
absence peptide mass profile matrix of 38 of the in total
40 samples in a heat-map. Peptide masses present in gli-
oma vessels clustering visually together in the red heated
area in the marked blue box. This helps selecting the pep-
tide masses to search for proteins in the SwissProt™ data-
base using the MASCOT™ search engine. The clustering
table is added as the Additional file 7. Two samples, S5
and TS5, were excluded because they could not be cali-
brated. Sample S10 appears to be an outlier in Figure 3,
since it is clustered between samples H6 and H7 and other
glioma samples. Peptide masses clustering to glioma ves-
sels, illustrated in the highlighted box of Figure 3 are sub-
mitted to the SwissProt™ database (version 40.21, entry
homo sapiens) using the MASCOT™ search engine to
identify the proteins differentially expressed in the "gli-
oma vessels" samples. A peptide mass error tolerance of ±
2 ppm is used with the MASCOT™ search. The highlighted
box in Figure 3 represents the hierarchical clustering order
490 with mass 1037.5355 Da to 789 with mass
1665.7891 Da (see Additional file 7). Only proteins that
have at least two matched values of experimental and cal-
culated peptide masses are taken into consideration. One
of the top 20 proteins reported by MASCOT™ is hemo-
globin alpha subunit with SwissProt™ accession code
P69905 with 2 matched peptide masses. Hemoglobin
alpha subunit is identified by the MS-MS sequencing
options of the WARP-LC™ software in the glioma vessels
(Additional file 1). Hemoglobin delta subunit with Swiss-
Prot™ accession code P02042 is also found is with 2
matched peptide masses. It is identified by the MS-MS
Table 3: Mass accuracy of peptide masses when measured with FTICR MS.
Average mass accuracy in 
ppm from calculated masses
Standard deviation in ppm
Theoretical with zero-filling factor 4 1.05 0.27
Data analysis 3.4 (Build 169) peak-list of sample H7 masses with intensities higher than a 
threshold of signal to noise 1.7
0.81 0.59
Peak list of sample H7 exported from this application with masses with intensities higher 
than a threshold of signal to noise 4
1.10 0.91
Masses in the peptide profile matrix which are present in 5 or more samples of total 38 
samples
1.03 0.72
Masses in the peptide profile matrix, which are present in 18 samples or more of total 
38 samples
0.67 0.48
20 peak masses with the highest mean peak intensities based on 586 peak and 
background signals
0.91 0.58
20 peak masses with middle mean peak intensities based on 383 peak and background 
signals
0.66 0.39
20 peak masses with the lowest mean peak intensities based on 254 peak and 
background signals
1.54 0.82
Measured on Glial fibrillary acidic protein (GFAP) with SwissProt™ accession code : P14136, masses MH+: 856.4523, 906.46795, 911.45811, 
986.52653, 988.5058, 1032.52076, 1039.55307, 1042.60036, 1050.52143, 1087.5742, 1098.62654, 1103.53273, 1108.47613, 1117.57353, 
1177.62113, 1208.59055, 1215.63277, 1244.65934, 1245.66846, 1263.63274,1277.70995, 1357.75461, 1405.80492, 1409.74227, 1499.78523, 
1505.76281, 1629.93224, 1634.76897, 1697.79852, 1746.91329, 1841.97153, 1853.89963, 1878.96679, 2075.14949, 2332.9597, 2348.14766 Da
Measured on Keratin, type I cytoskeletal 10 with SwissProt™ accession code: P13645, masses MH+ : 847.45197, 995.51965, 1031.59829, 
1109.48979, 1118.50858, 1165.58475, 1201.61713, 1234.67896, 1237.58476, 1262.59711, 1324.61679, 1365.6393, 1381.6481, 1390.68082, 
1434.76995, 1493.73429, 1707.77202, 1797.01158, 1996.97095, 2025.94334, 2096.04671, 2224.14169, 2295.12852, 2367.26265, 2872.39273, 
3052.62729 Da.
The mass accuracy is determined on tryptic fragments. The experimental mass accuracy was determined from the calculated value of tryptic peptide 
fragments of 2 proteins; 1) Glial fibrillary acidic protein with entry name GFAP_HUMAN and SwissProt™ accession number P14136, and 2) Keratin, 
type I cytoskeletal 10 with entry name K1C10_HUMAN and SwissProt™ accession number P13645.BMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
Page 10 of 21
(page number not for citation purposes)
sequencing options of the WARP-LC™ software in the gli-
oma tissue and vessels (Additional file 1). Other proteins
found by the MASCOT™ search engine are Fibrinogen beta
chain precursor with SwissProt™ accession code P02675
with 8 matched peptides masses and Fibrinogen gamma
chain precursor with SwissProt™ accession code P02679
with 4 matched peptide masses, both identified by MS-MS
(Additional file 1). The finding of hemoglobin and fibrin-
ogen is expected, since blood proteins and clotting pro-
teins are present in the lumina of the relative larger vessels
as compared to normal vessels. Other proteins in the
highlighted box found with the MASCOT™ search engine
with 2 matched peptides are Tubulin-specific chaperone A
with SwissProt™ accession code O75347, Fatty acid-bind-
ing protein, epidermal (E-FABP) with SwissProt™ acces-
sion code Q01469 (B-FABP is analyzed in glioma tissue
and vessels, see Additional file 1), Neutrophil gelatinase-
associated lipocalin precursor (NGAL) with SwissProt™
Heat-map of the hierarchical clustering on the presence-absence peptide mass profile matrix in two dimensions of the 38 sam- ples and 2375 peptide masses Figure 3
Heat-map of the hierarchical clustering on the presence-absence peptide mass profile matrix in two dimen-
sions of the 38 samples and 2375 peptide masses. The data of the clustering table is added as an additional file 7. A 
number of 10 spectra of glioma blood vessels with codes H1 to H10, 10 spectra of tissue surrounding the glioma vessels with 
codes TH1 to TH10, 10 spectra of normal vessels with codes S1 to S10, and 10 spectra of tissue surrounding the normal ves-
sels with codes TS1 to TS10 are included. Two "normal vessels" samples, S5 and TS5, were excluded because they could not 
be calibrated. The highlighted box in Figure 3 represents the hierarchical clustering order 490 with mass 1037.5355 Da to 789 
with mass 1665.7891 Da as presented  (see Additional file 7).BMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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accession code P80188, Peptidyl-tRNA hydrolase 2, mito-
chondrial precursor with SwissProt™ accession code
Q9Y3E5, Growth hormone variant precursor (GH-V)
(Placenta-specific growth hormone) with SwissProt™
accession code P01242 and Zinc finger CCHC domain
containing protein 13 with SwissProt™ accession code
Q8WW36.
Wilcoxon-Mann-Whitney
The list of p-values based on the peak intensity differences
between the normal and glioma vessel sample group for
2375 peptide masses is presented in the Additional file 2.
A number of 95 (4%) in glioma vessels up-regulated pep-
tide masses with p-values < 0.01 are used in MASCOT™ to
search for calculated peptides masses of proteins. A mass
tolerance of 2 ppm is used. The MASCOT™ search is
repeated with another number of 442 (19%) in glioma
vessels up-regulated peptide masses with p-values < 0.1.
Table 4 summarizes the MASCOT™ search and MS-MS
sequencing results of the differentially expressed proteins.
Only proteins are listed that have at least three experimen-
tal measured peptide masses that correspond with the cal-
culated values of these proteins. In Table 4, Calcium-
binding protein p22 is one of the proteins with 3 peptides
Increased peak intensity at the mass MH+ 1508.7103 Da from a peptide of probably Calcium-binding protein p22 in glioma ves- sel samples Figure 4
Increased peak intensity at the mass MH+ 1508.7103 Da from a peptide of probably Calcium-binding protein 
p22 in glioma vessel samples. The MALDI-FTICR Calcium-binding protein p22 peptide peaks of glioma samples are repre-
sented by the dark lines (by contrast the peptide mass of 2',3'-cyclic-nucleotide 3'-phosphodiesterase at 1508.8739 Da repre-
sented by the grey lines is as expected not present in glioma vessels).BMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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with a p-value < 0.1 that match with the SwissProt™ data-
base. An increased intensity of a peak at peptide mass
MH+ of 1508.7103 Da of likely a peptide of Calcium-
binding protein p22 is measured in glioma vessel samples
represented by the dark lines in Figure 4, which shows a
fraction of the MALDI-FTICR mass spectra of all samples.
By contrast the peptide mass of 2',3'-cyclic-nucleotide 3'-
phosphodiesterase (CNPase) at 1508.8739 Da repre-
sented by the grey lines is as expected not present in gli-
oma vessels. This protein is identified by MS-MS
sequencing in normal tissue and vessels (see Additional
file 1).
Peptide masses exclusively present in glioma vessels
The peptide masses which are exclusively present in the
glioma vessels group (series H in Additional file 8) are
used to search calculated masses of proteins using MAS-
COT™ with a mass tolerance of 2 ppm. In Table 5, all pro-
teins are listed that have 2 hits or more by a MASCOT™
search and one of these matched peptide masses has a
Wilcoxon-Mann-Whitney p-value < 0.01. MASCOT™ lists
proteins due with a score. However, peptides masses can
be ascribed to more than one protein in this summary.
Peptide masses are preferably ascribed to proteins present
in the MS-MS runs (Additional file 1) than proteins with
the highest score in the MASCOT™ summary. Calcium-
binding protein p22 with SwissProt™ accession number
Q99653 which was found with the Wilcoxon-Mann-Whit-
ney test is also added to Table 5. From the proteins listed
in Table 5, Fibronectin precursor and Myosin-9 are also
identified with the MS-MS sequencing of the pooled sam-
ples (Additional file 1), while Cdc42 effector protein 3
and Calcium-binding protein p22 are not identified by
MS-MS sequencing. Except for a small peak in the outlier
sample S10, Collagen-binding protein 2 precursor (Colli-
gin-2) with SwissProt™ accession code P50454 is exclu-
sively measured in the glioma vessels group (series H)
using the new algorithm. Collagen-binding protein 2 pre-
cursor (Colligin-2) is listed in a separate Table 6. The peak
intensities of the glioma samples are just above 300*103
A.U. and the value of S10 just under this value (Additional
file 2).
Myosin-9
From Table 5 it appears that peptides with mass
1869.9677, 1155.6643, 1949.9955, 2493.1740, and
2472.1699 of Myosin-9 are exclusively measured in the
glioma vessels, while other peptides masses of Myosin-9
are more randomly distributed among the different
groups, including normal vessels, glioma tissue, and nor-
mal tissue. Three peptides with different Wilcoxon-Mann-
Whitney p-values, 0.00170, 0.04085, and 0.75200 are
peptides of Myosin-9 identified by MS-MS sequencing
(Additional file 1). Two of them are displayed in Figure 5
and 6. Figure 5 shows a fraction of the mass spectra of all
samples, where the peak at peptide mass MH+  of
1155.6643 Da of Myosin-9 displays an increased intensity
in glioma samples represented by the dark lines, while the
first isotopic mass of Neurofilament triplet L protein at
1154.7128 Da, represented by the grey lines, is as
Table 4: Proteins significantly up-regulated in the "glioma vessels" group with respect to the "normal vessels" group.
Name SwissProt™ 
acc. code
Nr. hits p-
value< 0.01
Nr. hits p-
value< 0.1
MS-MS glioma 
vessels
MS-MS glioma 
tissue and vessels
MS-MS normal 
vessels
MS-MS normal 
tissue and vessels
Vimentin P08670 12 18 yes yes no no
Glial fibrillary acidic 
protein (GFAP)
P14136 3 12 yes yes yes yes
Serum albumin 
precursor
P02768 4 10 yes yes no no
Annexin A5 P08758 2 5 no yes no no
Actin, cytoplasmic 1 
(Beta-actin)
P60709 0 12 yes yes yes yes
Keratin, type I 
cytoskeletal 10
P13645 0 8 yes no yes no
Actin, alpha cardiac 
(Alpha-cardiac actin)
P68032 0 7 no yes no yes
Desmin P17661 0 6 no yes no no
Calcium-binding 
protein p22 
(Calcium-binding 
protein CHP)
Q99653 0 3 no no no no
A number of 95 (4%) of the measured peptide masses with Wilcoxon-Mann-Whitney p-values < 0.01 and raised intensities in the glioma vessel 
group are compared with calculated peptide masses from proteins in the SwissProt™ database using MASCOT™. A mass tolerance of 2 ppm is 
used. The MASCOT™ search is repeated with another number of 442 (19%) of peptide masses that have a p-value < 0.1 and with up-regulated 
intensities in the "glioma vessels" group. Only proteins are listed that have at least three hits of experimental measured peptide masses 
corresponding within 2 ppm with the calculated peptide masses of these proteins.BMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
Page 13 of 21
(page number not for citation purposes)
Table 5: Proteins associated with glioma vessel formation established from enzymatic digested by trypsin peptide masses that are 
exclusively present in the "glioma vessels" group.
Measured mass 
MH+ (Da)
Calculated mass 
MH+ (Da)
ppm p-value Intensity H 
against S
Intensity H > S Glioma 
vessels (H)
Normal 
vessels (S)
Glioma 
tissue(TH)
Normal 
tissue (TS)
SwissProtTM accession code Q9UKI2, name: Cdc42 effector protein 3 (Binder of Rho GTPases 2)
1229.6644 1229.66365 0.61 0.00411 yes 6 0 0 0
1656.8022 1656.80295 0.45 0.13120 yes 5 1& 00
1620.7609 1620.76073 0.10 0.25509 yes 4 0 0 0
1772.8870 1772.88871 0.96 0.80459 no 3 3 1 1
SwissProtTM accession code, name: Fibronectin precursor (FN) (Cold-insoluble globulin) (CIG)
1807.9063 1807.90469 0.89 0.00089 yes 8 0 0 0
1355.6954 1355.69536 0.03 0.00125 yes 7 0 0 0
1625.8539 1625.85196 1.19 0.00232 yes 5 0 0 0
1349.6848* 1349.68481 0.01 0.00345 yes 7 0 0 0
1926.0516 1926.04832 1.70 0.00503 yes 8 1& 00
1629.8728* 1629.87067 1.31 0.00873 yes 5 0 0 0
2470.3200 2470.31874 0.51 0.01233 yes 7 1 1 0
1078.5537 1078.55275 0.88 0.01835 no 0 3 1 1
1818.9739 1818.97078 1.72 0.02049 yes 5 0 0 0
2524.3649 2524.36568 0.31 0.02049 yes 5 0 0 0
1401.6649* 1401.66580 0.64 0.02170 yes 6 0 0 0
1341.6739 1341.67570 1.34 0.02663 yes 5 1 3 0
1110.5413 1110.54257 1.14 0.06243 yes 4 0 2 0
1593.8126 1593.81186 0.46 0.06243 yes 6 1 1 0
1292.6740 1292.67324 0.59 0.06373 yes 5 1 0 1
1297.7117 1297.71102 0.52 0.09473 yes 3 0 1 1
1591.8091 1591.80744 1.04 0.12668 yes 4 0 2 0
1235.5266 1235.52620 0.32 0.13120 yes 3 1 0 1
1431.7507 1431.74915 1.08 0.18754 yes 5 2 0 0
2139.9619 2139.96514 1.51 0.45543 yes 5 1 6 0
858.4301 858.43157 1.71 0.95436 no 2 1 2 0
1291.7265 1291.72560 0.70 1.00000 yes 3 3 1 0
SwissProtTM accession code Q99653, name: Calcium-binding protein p22 (Calcium-binding protein CHP) (Calcineurin homolo-
gous protein)
960.5588 960.55850 0.31 0.02082 yes 6 0 4 0
1138.5646 1138.56262 1.74 0.00959 yes 5 0 0 1
1508.7103 1508.70876 1.02 0.05363 yes 5 0 0 0
SwissProtTM accession code P35579, name: Myosin-9 (Myosin heavy chain, non-muscle IIa)
1869.9677* 1869.96645 0.67 0.00170 yes 6 0 0 0
1155.6643 1155.66325 0.91 0.00310 yes 5 0 0 0
1949.9955 1949.99268 1.45 0.01285 yes 8 0 0 0
2493.1740* 2493.17392 0.03 0.04085 yes 6 0 0 0
2472.1699 2472.17356 1.48 0.05363 yes 5 0 0 0
1393.7099# 1393.71102 0.80 0.07335 no 1 4 3 7
1946.0059 1946.00765 0.90 0.33559 yes 7 4 6 0
924.4946 924.49377 0.90 0.60387 yes 3 2 3 0
1309.6023† 1309.60188 0.32 0.61715 yes 4 3 1 0
1193.6166* 1193.61606 0.45 0.75200 yes 3 2 4 2
1310.7038$ 1310.70626 1.88 1.00000 yes 1 0 7 0
The listed proteins are found by a MASCOT™ search with 2 or more hits between measured and calculated tryptic peptide masses with an error 
tolerance of 2 ppm. Only proteins are listed that had at least one peptide mass with a Wilcoxon-Mann-Whitney p-value < 0.01 comparing the peak 
intensities of glioma vessels with normal vessels.
* WARP-LC MS-MS MALDI-TOF glioma tissue and vessels (see Additional file 1).
# SwissProtTM accession code:  P40925, name: Malate dehydrogenase, cytoplasmic, identified by WARP-LC MS-MS on glioma tissue and vessels and 
normal tissue and vessels (see Additional file 1).
†  SwissProtTM accession code: P08670, name: Vimentin, sequence: NLQEAEEWYK, MALDI TOF MS-MS by hand on the “glioma tissue and vessels” 
LC-MALDI plate using the BiotoolsTM 3.0 (build 1.68)  software.
$ SwissProtTM accession code:  P62805, name: Histone H4, identified by WARP-LC MS-MS on glioma tissue and vessels and normal tissue and 
vessels (see Additional file 1).
& outlier sample S10.BMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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expected not present in glioma vessels. Neurofilament tri-
plet L is identified by MS-MS sequencing in the "normal
tissue and vessels" sample (see Additional file 1). Figure 6
shows an equal distribution of peak intensities among all
samples of a Myosin-9 peptide mass at 1193.6166 Da. The
strong up-regulated peptides of Myosin-9 are all located at
the C-terminus of the protein, approximately from
amino-acid position 1301 to 1959 (Figure 7). Table 7
shows the Wilcoxon-Mann-Whitney p-values of peptide-
masses of Myosin-9 based on differences in peak intensi-
ties of each mass between the glioma vessels (series H)
and normal vessels (series S) samples. The p-values are
presented in the order of amino acid position of the pep-
tide from the N-terminus of the protein. The p-value grad-
ually drops from 0.60387 to 0.00310 from start positions
711 to 1923 of the amino acid sequences in the protein.
The C-terminus of the tryptic fragment with mass
1155.6643 Da is amino acid sequence RR and known to
be cut by trypsin at a lower rate. This explains the relative
low peak intensity of 82*103 and 7*103 A.U. for glioma
Increased peak intensity at the mass MH+ 1155.6643 Da from a peptide of Myosin-9 in glioma vessel samples Figure 5
Increased peak intensity at the mass MH+ 1155.6643 Da from a peptide of Myosin-9 in glioma vessel samples. 
The peaks of glioma vessel samples are represented by the dark lines in MALDI-FTICR mass spectra of all samples. The first 
isotopic mass of Neurofilament triplet L protein at 1154.7128 Da, represented by the grey lines, is as expected not present in 
Glioma vessels.
Table 6: Distribution of tryptic peptide fragments of colligin-2 among the tissue sections of different groups Peptide masses obtained 
by MALDI-FTICR MS are listed that match within 2 ppm with the calculated values of enzymatic by trypsin digested fragments.
SwissProt™ accession code P50454, name: Collagen-binding protein 2 precursor (Colligin 2)
Measured mass 
MH+ (Da)
Calculated mass 
MH+ (Da)
ppm p-value Intensity H 
against S
Intensity H > S Glioma 
vessels (H)
Normal 
vessels (S)
Glioma 
tissue (TH)
Normal 
tissue (TS)
1021.5304 # 1021.53213 1.69 0.77475 no 1 2 0 3
1293.6805 1293.67973 0.60 0.01244 yes 5 1 1 3
1659.8011 * 1659.80126 0.10 0.02170 yes 5 1& 00
1675.7747 ? 1675.77577 0.64 0.01088 yes 1 0 2 4
* WARP-LC MS-MS MALDI-TOF glioma tissue and vessels (see additional file 1)
# SwissProt™ accession code: P07196, name: Neurofilament triplet L protein, identified by WARP-LC MS-MS MALDI-TOF on normal tissue and 
vessels (see additional file 1)
? SwissProt™ accession code: P17677, name: Neuromodulin (Axonal membrane protein GAP-43) ?
&outlier sample S10BMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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vessels and normal vessels, respectively (Table 7). By con-
trast, the p-value of peptides of fibronectin precursor in
Table 5 remains constant. Some examples throughout dif-
ferent positions in the protein are a p-value of 0.02170 for
the mass at 1401.6649 Da at start position 58, a p-value of
0.00503 for the mass at 1926.0516 Da at the middle posi-
tion 1285, and a p-value of 0.02049 for the mass at
1818.9739 Da at the end position 2165 of the protein.
Discussion
Candidate glioma vessel formation biomarkers
In this study, proteins of laser micro-dissected tissues are
analyzed using an improved high sensitivity detection,
thus lower S/N threshold in comparison with our previ-
ous experiments [1]. Fibronectin precursor is 'rediscov-
ered'. The mass 1275.5568 Da previously ascribed to
acidic calponin [1] is measured again, however it differs
relative much with 2.5 ppm from the calculated mass of
1275.5600 Da in this analysis. It is 5 times measured in
the glioma vessels, 2 times in the normal vessels (includ-
ing the outlier sample S10 in hierarchical clustering) and
not in the other tissues. The mass 1659.8009 Da of Colli-
gin-2 is measured again (Table 6) with 0.10 ppm mass
accuracy. Cytoskeleton proteins and proteins involved in
the calcium signaling pathway seem to be most up-regu-
lated. Tubulin-specific chaperone A is likely to be detected
by hierarchical clustering and reported to be biomarker
for grade IV gliomas [19,20]. Annexin A5, detected with
the Wilcoxon-Mann-Whitney test, is an ion channel pro-
tein with calcium- and phospholipid-binding properties.
Calcium-binding protein p22 is a member of the calcium
signaling pathway [21]. It is interesting that the mass of
1116.54323 Da was not identified in our previous study
[1] matches with 0 ppm with a tryptic fragment of Cal-
cium/calmodulin-dependent 3',5'-cyclic nucleotide phos-
phodiesterase 1C with SwissProt™ accession code
Q14123, while the mass of 2157.1065 Da matches with
0.38 ppm with a tryptic fragment of Calcium/calmodulin-
dependent protein kinase kinase 2 with SwissProt™ acces-
sion code Q96RR4. Both proteins belong to the same cal-
cium signaling pathway [21]. The finding of only part of
fragments of Myosin-9 up-regulated in the glioma vessel
samples may have various reasons. It could be ascribed to
splicing, fragmentation of Myosin-9 by proteases, or other
technical and concentration related reasons. It is not unu-
sual that some peptides or part of one protein may be up-
regulated in one group. In a previous peptide-profiling
study between a control and an end stage prostate cancer
group (Figure 10 in ref. [2]), simultaneously up-regulated
tryptic and down-regulated semi-tryptic peptide masses of
An equal distribution of peak intensities among all samples of a Myosin-9 peptide mass at 1193.6166 Da Figure 6
An equal distribution of peak intensities among all samples of a Myosin-9 peptide mass at 1193.6166 Da. The 
dark lines represent the peak intensities of the glioma vessel samples.BMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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Strong up-regulated peptides of Myosin-9 in the "glioma vessels group" versus the "normal vessels group" located at the C-ter- minus of the protein Figure 7
Strong up-regulated peptides of Myosin-9 in the "glioma vessels group" versus the "normal vessels group" 
located at the C-terminus of the protein. The strong up-regulated peptides are approximately located from amino-acid 
position 1301 to 1959.B
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Table 7: Wilcoxon-Mann-Whitney p-values of Myosin-9 peptide peak mass intensities between the "glioma vessels" (series H) and "normal vessels" (series S) The p-value gradually drops 
from 0.60387 to 0.00310 from start position 711 to 1923 of the amino acid in the protein.
MS-MS Position start Position end Observed mass 
MH+
Calculated 
mass MH+
ppm Missed 
cleavages
Sequence Wilcoxon-
Mann-Whitney 
p-value
Mean intensity 
glioma vessels (H) 
*103 (A.U.)
Mean intensity 
normal vessels (S) 
*103 (A.U.)
Intensity H/S
711 717 924.4946 924.49373 0.94 0 R.VVFQEFR.Q 0.60387 117 30 4
* 745 754 1193.6166 1193.61604 0.47 0 K.ALELDSNLYR.I 0.75200 100 44 2
1277 1294 1946.0059 1946.00763 0.89 0 K.LQVELDNVTGLLSQS
DSK.S
0.33559 287 179 2
* 1301 1321 2493.174 2493.17392 0.03 0 K.DFSALESQLQDTQEL
LQEENR.Q
0.04085 211 45 5
1417 1432 1949.9955 1949.99268 1.45 0 R.LQQELDDLLVDLDH
QR.Q
0.01285 264 95 3
1730 1750 2472.1699 2472.17356 1.48 0 R.IAQLEEELEEEQGNTE
LINDR.L
0.05363 154 11 14
* 1754 1769 1869.9677 1869.96645 0.67 0 K.ANLQIDQINTDLNL
ER.S
0.00170 263 39 7
1923 1932 1155.6643 1155.66325 0.91 1 R.GDLPFVVPRR.M 0.00310 82 7 11
* WARP-LC MS-MS MALDI-TOF glioma tissue and vessels (see additional file 1)BMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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one protein, namely human serum albumin affected by
proteases were measured [22]. Some part of myosin-9 has
a specific function since calponin binds (in addition to
calmodulin) a specific region S2 of the Myosin-9 rod to
actin [23]. Some relatively high p-values for fibronectin in
Table 5 can be ascribed by wrongly clustered peptide
masses of other proteins than fibronectin. Caldesmon
binds Myosin-9 in the same S2 region. It is interesting that
Glia maturation factor gamma (GMF-gamma) with Swiss-
Prot™ accession code O60234 is another protein preferen-
tially expressed in human micro vascular endothelial cells
that modulates actin cytoskeleton reorganization [24]. It
could be measured in glioma vessels with one mass of
1762.8413 Da and a low Wilcoxon-Mann-Whitney p-
value of 8.7 *10-3. Glia maturation factor gamma is meas-
ured co-expressed with CDC42 effector protein 3 in stro-
mal vascular cells (see Table 3 in ref. [25]). It is suggested
that Glia maturation factor gamma in combination with
the protein CDC42 plays a role in angiogenesis [24].
Mass accuracy
The theoretical mass accuracy is about 1.05 ± 0.27 ppm
for the FTICR MS instrument used without centroiding. It
decreases to 0.67 ± 0.48 ppm when determined on pep-
tide masses, which appear to be presents in 18 samples or
more in the peptide matrix of in total 38 samples. Proba-
bly, centroiding of the mean peptide mass takes place
when taking the average over more samples. In a single
high resolution MALDI-FTICR spectrum the real peak
mass is between the data point with the local highest
intensity and some of the data points with the next high-
est intensities. The measured peak mass of the data point
with the highest local intensity is by change 50% left or
right from the real peak maximum. It is hard to distin-
guish centroiding from effects of the dynamic range or
ion-statistics. The mass accuracy decreases for peaks with
low intensity. The peaks less frequently measured in all
samples are probably also the less intensive which results
in less accurate masses (Table 3). To limit performance
problems a relative large peak search window of 20 ppm
is chosen. The most abundant proteins have always the
largest peak intensities within this window and the pep-
tide masses of these proteins are chosen by the algorithm.
There is more competition among the peptides of less
abundant proteins with about equal low intensities. May
be the combination of peptides from different proteins is
the reason that the mass averaging does not improve accu-
racies by reducing statistical deviations for small peaks.
The observation that the most intensive peaks do not have
necessary the highest accuracy supports an additional
effect of centroiding. A further improvement of the mass
accuracy would significantly increase the reliability and
direct identification of candidate proteins found using the
MASCOT™ search engine on the SwissProt™ database. We
applied a centroiding by a weighted mean calculated with
various mass windows to 20 ppm in both directions of the
peak mass, which is about the size of the peak-width, with
a total window of 40 ppm. This did not improve the accu-
racy of the measured peptide masses, probably because
the peaks are not symmetric. The larger number of peptide
masses obtained by LC-MS demonstrates that there are a
lot of overlapping peptide masses. This problem was rec-
ognized by Strittmatter et al. [26] who applied a double
Gaussian fit to eliminate shoulders on the asymmetric
peak distribution to get a more accurate mass. A double
Gaussian fit is a special case of a Gaussian Mixture Mode-
ling (GMM) [27-31], where 2 Gaussian curves are fitted
through the peak distribution, with two maximum inten-
sities at mass1 and mass2 separated by a distance Δ, thus
mass1 – mass2 = Δ. We encounter the same failure of less
likelihood of a convergence of masses, where mass1 =
mass2 when applying a double Gaussian fit, but don't like
to use the fixed Δ as suggested in [26].
De-isotope algorithm
The introduced de-isotope algorithm, which only
removes peaks which are isotopes in an initial window of
1.0034 ± 0.0100 Da leads to more peptide masses com-
pared to the commercial software in the processed peak
lists and consequently to more hits with calculated pep-
tide masses of proteins in the SwissProt™ database by
using the MASCOT™ search engine. Although we obtained
satisfactory results with the de-isotope algorithm, the rel-
ative intensities of peaks within the isotopic clusters also
should be compared with the theoretical distributions.
Especially, the high masses display a larger scatter of iso-
topic distance and could easily fall outside the restrictive
acceptance window (Figure 2). Ideally, it should be an
(equipment dependent) function of mass. Since the iso-
topic distribution of individual elements, C, H, N, O and
S of peptides is known, the abundance for each permuta-
tion of individual elements can be calculated with a multi-
nomial distribution and the total number of atoms of the
element in the peptide [32]. Combining the abundances
for all the known number of different elements in a pep-
tide, the isotopic distribution for a peptide can be calcu-
lated. Senko [13] calculates the number of each element
C, H, N, O and S in a peptide by division of the peptide
mass by the mass of a theoretical "averagine" amino acid,
while Gay and co-workers [11] used all the tryptic frag-
ments of the SwissProt™ database in a mass window. This
resulted in a plot of the percentage intensity distribution
of the 5 isotopes M0, M1+, M2+, M3+, M4+, and M5+ as a
function of the peptide mass in Da. Samuelsson and co-
workers [12] have developed an algorithm to determine
the mono-isotope masses in an overlapping cluster com-
paring the measured with the expected intensity distribu-
tion of the isotopic masses in a cluster. Valkenborg and
co-workers [9] can distinguish peptides containing 0, 1
and 2 sulfur atoms from isotopic clusters, which wouldBMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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help with the analysis of proteins. The database applica-
tion with such an algorithm can result in finding reliable
mono-isotopic masses and perhaps leads to more protein
identifications.
Conclusion
A database application is presented that can compare
hundreds of raw high resolution FTICR mass spectrometry
files without serious performance limitations. A new less
rigorous than commercial propriety software de-isotope
algorithm is introduced, that results in more mono-iso-
topic peptide masses and consequently more protein
identifications. From the peptide masses in the mass spec-
trometry files 2 peptide profile matrices are created taking
the average of peptide masses in different samples within
a mass window of 3 ppm and listing for the individual
samples the 1) presence or absence of the peptide peaks
and 2) peak intensities. The mass accuracy of the Java™
application is predominantly influenced by the data point
resolution in the raw FTICR mass spectrometry files. Cen-
troiding of peptide masses takes place by taking the aver-
age over more spectra in the profile matrix. The usage of
raw MS spectra instead of peak lists results in a more reli-
able comparison of peak intensities between groups. The
Wilcoxon-Mann-Whitney test can be performed on the
intensity matrix, using raw spectrometry data. From this
test it appears that cytoskeleton proteins and proteins
involved in the calcium signaling pathway seem to be
most up-regulated. Tryptic fragments at the C-terminus of
the Myosin-9 protein are more up-regulated in glioma
vessels compared to the peak intensities observed in nor-
mal vessels. The Wilcoxon-Mann-Whitney p-values of
peptide fragments show a significant decline from the N-
terminus of Myosin-9. The software described in this
paper gives a new opportunity to find and quantify signif-
icantly differentially expressed peptides close to noise
level in clinical samples.
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Additional file 1
MS-MS sequencing analysis results of the "glioma vessels", "normal 
vessels", "tissue surrounding the glioma vessels", and "tissue sur-
rounding the normal vessels" samples. A BTDX.xml file exported by the 
WARP-LC™ software, containing the MS and the MS-MS peak masses, is 
imported in Biotools™ 3.0 (build 1.68) (Bruker Daltonics, Germany) and 
submitted by this software application to the SwissProt™ version 40.21 
database, using the MASCOT™ search engine, allowing 150 ppm parent 
mass tolerance, 0.5 Da fragments tolerance, and one missed trypsin cleav-
age site.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-133-S1.csv]
Additional file 2
Wilcoxon-Mann-Whitney p-values of the intensities of peak masses 
between the "glioma vessels" and "normal vessels" group. The Wil-
coxon-Mann-Whitney p-values are calculated based on intensity differ-
ences of peak masses between the "glioma vessels" and "normal vessels" 
group. The p-values are presented as well up-regulated (+) as down-regu-
lated (-) in the "glioma vessels" group.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-133-S2.csv]
Additional file 3
Peptide peak masses and intensities list exported from the database appli-
cation with a signal to noise (S/N) ratio > 4.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-133-S3.csv]
Additional file 4
Peptide peak masses and intensities list exported from the DataAnalysis™ 
3.4 (Build 169) software with a signal to noise (S/N) ratio > 1.7.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-133-S4.csv]BMC Bioinformatics 2008, 9:133 http://www.biomedcentral.com/1471-2105/9/133
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